Top

Published in:

01-09-2015 | Research Article

ShRNA-mediated knock-down of CXCR7 increases TRAIL-sensitivity in MCF-7 breast cancer cells

Authors: Weiran Gao, Xifan Mei, Jikun Wang, Xianglin Zhang, Yajiang Yuan

Published in: Tumor Biology | Issue 9/2015

Abstract

This study aims to investigate the effects of CXCR7-shRNA on TRAIL-mediated apoptosis and suppression of invasive migration and the underlying mechanisms. (1) We constructed CXCR-7-shRNA lentiviral vectors and confirmed their silencing efficiency in MCF-7 cells by RT-PCR analysis. (2) The effects of CXCR7 and/or TRAIL on cell proliferation were examined by MTT assay. (3) Trans well invasion assay was used to examine the effects of CXCR7 silencing and/or TRAIL on MCF-7 cell invasive migration. (4) Expression of Caspase-3, and Caspase-8, and MMP-2 and MMP-9 proteins was examined by Western blot analysis. (1) Viral titers were 2.95 × 10⁸ TU/ml, 3.01 × 10⁸ TU/ml, 3.26 × 10⁸ TU/ml, and 3.08 × 10⁸ TU/ml, respectively. (2) CHXR7 shRNAs markedly decreased CXCR7 mRNA expression in MCF-7 cells, among which CXCR7-shRNA-1 showed significantly higher rate of inhibition (P < 0.05). (3) Combination of TRAIL and CXCR7-shRNA-1 resulted in marked suppression of cell proliferation in time-dependent manner (P < 0.05). (4) Cell invasion capacity was inhibited in each experimental group as compared to blank control group at 48 h post treatments (P < 0.05). Among them, combination of TRAIL and CXCR7-shRNA had the highest inhibitory effect (P < 0.05). (5) Western blot analysis indicated that TRAIL alone does not affect CXCR7 expression, but either TRAIL + CXCR7 shRNA or CXCR7 shRNA alone markedly suppressed CXCR7 protein expression. Furthermore, combination of TRAIL and CXCR-7-shRNA significantly increased Caspase-3 and Caspase-8 expression and decreased MMP-2 and MMP-9 expression (P < 0.05). Knock-down of CXCR-7 expression leads to augmented TRAIL-mediated suppression of MCF-7 cell proliferation and invasion.

De Luca A, D’Alessio A, Gallo M, Maiello MR, Bode AM, Normanno N. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle. 2014;13(1):148–56. doi:10.4161/cc.26899.CrossRefPubMed

Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74(6):1645–50. doi:10.1158/0008-5472.CAN-13-1739.CrossRefPubMedPubMedCentral

Yang Q, Zhang F, Ding Y, Huang J, Chen S, Wu Q, et al. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br J Cancer. 2014;110(5):1288–97. doi:10.1038/bjc.2014.1.CrossRefPubMedPubMedCentral

Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61(1):259–66. doi:10.1373/clinchem.2014.228122.CrossRefPubMed

Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21(4):899–906. doi:10.1158/1078-0432.CCR-14-0894.CrossRef

Holland JD, Gyorffy B, Vogel R, Eckert K, Valenti G, Fang L, et al. Combined Wnt/beta-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Reports. 2013;5(5):1214–27. doi:10.1016/j.celrep.2013.11.001.CrossRefPubMed

Sosinska-Mielcarek K, Duchnowska R, Winczura P, Badzio A, Majewska H, Lakomy J, et al. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. Breast. 2013;22(6):1178–83. doi:10.1016/j.breast.2013.08.011.CrossRefPubMed

Hung CS, Su HY, Liang HH, Lai CW, Chang YC, Ho YS, et al. High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35(2):1581–8. doi:10.1007/s13277-013-1218-9.CrossRef

Yang P, Liang SX, Huang WH, Zhang HW, Li XL, Xie LH, et al. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer. Curr Mol Med. 2014;14(1):174–84.CrossRefPubMed

10.

Ying J, Xu Q, Zhang G, Liu B, Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol. 2012;29(3):1716–22. doi:10.1007/s12032-011-9990-0.CrossRefPubMed

11.

Wang Y, Li G, Stanco A, Long JE, Crawford D, Potter GB, et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron. 2011;69(1):61–76. doi:10.1016/j.neuron.2010.12.005.CrossRefPubMedPubMedCentral

12.

Liu L, Zhao X, Zhu X, Zhong Z, Xu R, Wang Z, et al. Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. Mol Med Reports. 2013;8(1):140–6. doi:10.3892/mmr.2013.1477.

13.

Schanz A, Baston-Bust D, Krussel JS, Heiss C, Janni W, Hess AP. CXCR7 and syndecan-4 are potential receptors for CXCL12 in human cytotrophoblasts. J Reprod Immunol. 2011;89(1):18–25. doi:10.1016/j.jri.2011.01.016.CrossRefPubMed

14.

Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY, Ye SL. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep. 2013;30(1):105–10. doi:10.3892/or.2013.2442.PubMed

15.

Ren J, Zhang Y, Cai H, Ma H, Zhao D, Zhang X, et al. RNAi targeting GPR4 influences HMEC-1 gene expression by microarray analysis. Int J Clin Exp Med. 2014;7(3):607–15.PubMedPubMedCentral

16.

Zeng Z, Zhang C, Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts. J Bone Miner Metab. 2013;31(4):409–16. doi:10.1007/s00774-013-0434-0.CrossRefPubMed

17.

Lin Y, Cui M, Xu T, Yu W, Zhang L. Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells. Mol Med Reports. 2014;9(6):2499–504. doi:10.3892/mmr.2014.2131.

18.

Liu L, Zhang N, Liu J, Min J, Ma N, Liu N, et al. Lentivirus-mediated siRNA interference targeting SGO-1 inhibits human NSCLC cell growth. Tumour Biol: J Int Soc Oncodev Biol Med. 2012;33(2):515–21. doi:10.1007/s13277-011-0284-0.CrossRef

19.

Sun XY, Nong J, Qin K, Lu H, Moniri MR, Dai LJ, et al. MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res. 2011;31(11):3705–12.PubMed

20.

Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;15(2):188–200.CrossRefPubMedPubMedCentral

21.

Mohan RR, Rodier JT, Sharma A. Corneal gene therapy: basic science and translational perspective. Ocular Surface. 2013;11(3):150–64. doi:10.1016/j.jtos.2012.10.004.CrossRefPubMedPubMedCentral

22.

Bratton SB, MacFarlane M, Cain K, Cohen GM. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res. 2000;256(1):27–33. doi:10.1006/excr.2000.4835.CrossRefPubMed

23.

Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12(6):599–609.CrossRefPubMed

24.

Moulin M, Arrigo AP. Caspases activation in hyperthermia-induced stimulation of TRAIL apoptosis. Cell Stress Chaperones. 2008;13(3):313–26. doi:10.1007/s12192-008-0027-3.CrossRefPubMedPubMedCentral

25.

Movsesyan VA, Stoica BA, Yakovlev AG, Knoblach SM, Lea PM, Cernak I, et al. Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 2004;11(10):1121–32. doi:10.1038/sj.cdd.4401442.CrossRefPubMed

26.

Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34. doi:10.1007/s10555-006-7886-9.CrossRefPubMed

27.

Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem. 2006;281(23):15997–6005. doi:10.1074/jbc.M601223200.CrossRefPubMed

28.

Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6(6):449–58. doi:10.1038/nrc1886.CrossRefPubMed

Title: ShRNA-mediated knock-down of CXCR7 increases TRAIL-sensitivity in MCF-7 breast cancer cells
Authors: Weiran Gao
Xifan Mei
Jikun Wang
Xianglin Zhang
Yajiang Yuan
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3432-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights

Gender and plasma iron biomarkers, but not HFE gene mutations, increase the risk of colorectal cancer and polyps

The role of H. pylori infection in gall bladder cancer: clinicopathological study

Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression

A Aconitum coreanum polysaccharide fraction induces apoptosis of hepatocellular carcinoma (HCC) cells via pituitary tumor transforming gene 1 (PTTG1)-mediated suppression of the P13K/Akt and activation of p38 MAPK signaling pathway and displays antitumor activity in vivo

Expression of myeloid zinc finger 1 and the correlation to clinical aspects of oral squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer